IRB Preparation/Co-Investigator

  1. 2013 Prospective and Retrospective Screening for Hepatitis B, Hepatitis C and HIV in South Florida Community. UM-IRB #20120528.
  2. 2013 Performance Evaluation of Elecsys Anti-HCV II Immunoassay and PreciControls on the Cobas E601 Analyzer, Study No. CIM RD001453. UM-IRB #20130498.
  3. 2013 GS-US-337-0123- A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant. UM-IRB #20130470.
  4. 2013 Assessing Infection Prevalence and Molecular Determinants of Health Disparities in Hepatitis C Virus infected African Americans, Haitians, and Latinos for the Prevention of Hepatocellular Carcinoma. UM-IRB #20130272.
  5. 2012 Elucidation of the Role of Statins in the Treatment of Hepatocellular Carcinoma. UM-IRB #20120983.
  6. 2012 Effects of Asunaprevir and Daclatasvir versus the combination of peginterferon and ribavirin with Asunaprevir and Daclatasvir on Interferon Stimulated Gene Expression in Null and Partial Responders with Chronic Hepatitis C. Approved and Enrolling.
  7. 2008 Viral kinetics and liver gene expression in response to ribavirin and peginterferon for chronic hepatitis C. NIH Protocol 08-DK-0182.
  8. 2007 Effect of Pretreament Ribavirin on Response to Standard Hepatitis C Antiviral Therapy. Study #: 07-2582. UNC Biomedical IRB.
  9. 2007 Immunohistochemical Analysis of Patient Liver Biopsies Obtained During the AACT. Study #: 07-0202. UNC Biomedical IRB.
  10. 2007 Molecular Analysis of Liver Biopsies Obtained in Germany Under IRB Approved Protocol. Study #: 07-0151. UNC Biomedical IRB.